Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Global revenue of Gardasil and Cervarix from 2006–2018.

More »

Table 1 Expand

Table 2.

Number of Gardasil doses sold in different countries and country groups between 2010–2017 and forecasted quantities until 2027 (middle estimates), in millions.

More »

Table 2 Expand

Table 3.

Variable costs for manufacturing Gardasil, in 2018 US$.

More »

Table 3 Expand

Table 4.

Estimated PDV of the stream of operating profits (in million 2018 US$) for the periods 2020–2028 and 2007–2028, applying Eq No. 2.

More »

Table 4 Expand

Table 5.

Annual manufacturing fixed costs, in million 2018 US$.

More »

Table 5 Expand

Table 6.

PDV of the stream of fixed manufacturing and marketing costs from 2020–2028 and 2007–2028, in million 2018 US$, applying Eq No. 3.

More »

Table 6 Expand

Table 7.

Estimated global patent buyout price in 2020 and total patent value of Gardasil (2007–2028) in million 2018 US$, applying Eq No. 4.

More »

Table 7 Expand

Table 8.

Estimated R&D costs on subjects, site and study of Gardasil-4 and Gardasil-9 (in 2018 US$).

More »

Table 8 Expand

Table 9.

Total R&D cost derivation (in 2018 US$).

More »

Table 9 Expand